Pfizer Says ELREXFIO Phase 3 Trial Met Primary PFS Endpoint
Pfizer said MagnetisMM-32 met its primary endpoint, with ELREXFIO monotherapy reducing the risk of progression or death versus three standard regimens in RRMM. PFS was 68% at 18 months; median PFS was not yet reached. Overall survival data remain immature, and regulatory filings are planned.